title: MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients.
abstract: BACKGROUND
  Hepatitis C virus genotype 4 (HCV-4) infection is common in the Middle East and Africa, with an extraordinarily high prevalence in Egypt. MicroRNAs (miRNAs) play an important role in various diseases, including HCV infection. The aim of the present study was to assess serum miR-122, miR-221 and miR-21 expression profiles in HCV-4 patients prior to treatment with HCV-4 combination therapy (pegylated alpha interferon and ribavirin) and to determine whether the miRNAs were associated with the drug response.
  
  
  METHODS
  RNA was extracted from pretreatment serum samples, and miR-122, miR-221 and miR-21 levels were measured by quantitative PCR. The results were compared among patients with sustained virological responses (SVR) and non-responders (NR).
  
  
  RESULTS
  The expression levels of miR-21 and miR-122 were significantly different between the SVR and NR groups. Receiver operator characteristic (ROC) analysis revealed that the sensitivity, specificity and positive predictive values of miR-21 were 82.2%, 77.3% and 88.1%, respectively, with a cut-off value of 1.7. The sensitivity, specificity and positive predictive values of miR-122 were 68.9%, 59.1% and 77.5%, respectively, with a cut-off value of 3.5.
  
  
  CONCLUSIONS
  miR-21 and miR-122 might be useful predictors for SVR in HCV-4 patients prior to the administration of combination therapy. A higher predictive response power was obtained for miR-21 than for miR-122. These results should reduce ineffective treatments.
authors: Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
authors: Tarek M K
authors: TM
authors: Motawi
authors: Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
authors: Sherine M
authors: SM
authors: Rizk
authors: Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors: Olfat G
authors: OG
authors: Shaker
authors: New Educational El kasr El Aini Hospital, Cairo University, Cairo, Egypt.
authors: Olfat Z H
authors: OZ
authors: Mokhtar
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers; D016022:Case-Control Studies; D004534:Egypt; D005260:Female; D020869:Gene Expression Profiling; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008111:Liver Function Tests; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D012372:ROC Curve; D016896:Treatment Outcome; D019562:Viral Load; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D035683:MicroRNAs; D007372:Interferons